Company Research Report: Primaa

Company Overview

• Name: Primaa

• Mission: Primaa is committed to driving digital pathology innovation by harnessing AI for precise cancer diagnosis, improving healthcare, and empowering pathologists.

• Founded: 2018

• Founders: Marie Sockeel, Stéphane Sockeel, and Fanny Sockeel

• Key People:

• Fanny Sockeel (CEO)

• Dr. Marie Sockeel (Chief Medical Officer)

• Stéphane Sockeel (Chief Scientific Officer)

• Adrien Nivaggioli (Data Scientist)

• Ahmed Adam D'Ala (Software Engineer)

• Headquarters: 41 rue du sentier, 75002 Paris, France

• Number of Employees: 25

• Revenue: No information is available

• Known For: AI-based platforms for automated and accurate cancer diagnosis, particularly focused on digital pathology solutions such as Cleo Breast and Cleo Skin.

Products

Cleo Breast

• Description: An AI-powered diagnostic solution designed for automated detection and interpretation of breast cancer biomarkers.

• Key Features:

• Detection of invasive carcinoma and in situ carcinoma.

• Mitosis detection and automatic counting.

• Detection of calcifications and metastases.

• Integrated with laboratory workflows to offer smart work lists and automated slide prioritization.

• Complies with data protection regulations.

Cleo Skin

• Description: AI-powered diagnostic tool focusing on skin cancer, providing automated detection and measurement of skin lesions.

• Key Features:

• Detection and classification of melanoma, squamous-cell carcinoma, and basal-cell carcinoma.

• Automatic measuring of lesion dimensions and margins.

• Support for prioritization of urgent cases and integrated with laboratory workflow.

Recent Developments

• Scientific Publications:

• Standardized CycleGAN Training for stain adaptation in breast carcinoma classification (Jan 8, 2024).

• Multicenter detection of invasive carcinoma in breast slide images (Jan 25, 2024).

• Clinical Trials:

• Launched clinical trial for Cleo Breast to enhance breast cancer biomarker detection (June 14, 2023).

• Product Developments:

• Automated TILs scoring tool for invasive ductal carcinoma published (Oct 16, 2023).

• Automatic detection of malignant skin lesions introduced (Sep 23, 2023).

• End-to-end pipeline for automatic IHC grading in breast cancer launched (Sep 20, 2023).

Key Scientific Studies

• Time Savings: Study showing reduced detection time with Cleo Breast tool: -14% for carcinoma, -50% for mitoses, and -32% for macro-metastases (Nov 1, 2023).

Partnerships

• Collaborations: Trusted by leading organizations, collaborating with European reference laboratories and medical institutions like Institut Curie, Institut Bergonié, and others.

Additional Information

• Contact: contact@primaalab.com

• Note: Solutions are designed for research use only, not for diagnostic procedures unless otherwise stated.